



## HARMONY BIOSCIENCES ENTERS INTO \$185 MILLION TERM LOAN FACILITY

Jul 27, 2023 at 8:05 AM EDT

**Financing further strengthens balance sheet  
Use of net proceeds and existing cash to repay existing debt  
Reduces annual interest expense by approximately \$6 million**

PLYMOUTH MEETING, Pa., July 27, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced it has entered into a new \$185 million senior secured term loan facility with a bank syndicate. Harmony intends to use the net proceeds from the term loan and existing cash to repay the Company's existing debt of \$196.5 million and related fees and expenses. Additional information about the term loan is contained in the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on July 27, 2023.



"This financing further strengthens our balance sheet, provides greater financial flexibility and reduces our annual interest expense and overall cost of capital," said Jeffrey M. Dayno, M.D., President and CEO at Harmony Biosciences. "Our cash generation and profitability, along with our outlook for growth, made this financing possible. Harmony's business is strong, continues to be a growth story, and we look forward to working with J.P. Morgan and this banking syndicate to advance our growth strategy."

JPMorgan Chase Bank, N.A. serves as administrative agent, and acted as bookrunner and lead arranger, for the term loan facility.

### **About Harmony Biosciences**

At Harmony Biosciences, we specialize in developing and delivering treatments for rare neurological diseases that others often overlook. We believe that where empathy and innovation meet, a better life can begin for people living with neurological diseases. Established by Paragon Biosciences, LLC, in 2017 and headquartered in Plymouth Meeting, PA, our team of experts from a wide variety of disciplines and experiences is driven by our shared conviction that innovative science translates into therapeutic possibilities for our patients, who are at the heart of everything we do. For more information, please visit [www.harmonybiosciences.com](http://www.harmonybiosciences.com).

### **Forward Looking Statement**

*This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including statements regarding our product WAKIX. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: our commercialization efforts and strategy for WAKIX; the rate and degree of market acceptance and clinical utility of WAKIX, pitolisant in additional indications, if approved, and any other product candidates we may develop or acquire, if approved; our research and development plans, including our development activities with Bioprojet and plans to explore the therapeutic potential of pitolisant in additional indications; our ongoing and planned clinical trials; the availability of favorable insurance coverage and reimbursement for WAKIX; the impact of the COVID-19 pandemic, including any current and future variants; the timing of and our ability to obtain regulatory approvals for pitolisant for other indications as well as any of our product candidates, including those we are developing with Bioprojet; our failure to achieve the potential benefits under our 2022 LCA with Bioprojet; our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; our ability to identify additional products or product candidates with significant commercial potential that are consistent with our commercial objectives; our commercialization, marketing and manufacturing capabilities and strategy; significant competition in our industry; our intellectual property position; loss or retirement of key members of management; failure to*

*successfully execute our growth strategy, including any delays in our planned future growth; our failure to maintain effective internal controls; the impact of government laws and regulations; volatility and fluctuations in the price of our common stock; the significant costs and required management time as a result of operating as a public company; the fact that the price of Harmony's common stock may be volatile and fluctuate substantially; and the significant costs and required management time as a result of operating as a public company. These and other important factors discussed under the caption "Risk Factors" in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC") on February 21, 2023, and our other filings with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.*

**Harmony Biosciences Investor Contact:**

Luis Sanay, CFA  
445-235-8386

[lsanay@harmonybiosciences.com](mailto:lsanay@harmonybiosciences.com)

**Harmony Biosciences Media Contact:**

Cate McCanless  
202-641-6086

[cmccanless@harmonybiosciences.com](mailto:cmccanless@harmonybiosciences.com)

 View original content to download multimedia: <https://www.prnewswire.com/news-releases/harmony-biosciences-enters-into-185-million-term-loan-facility-301886920.html>

SOURCE Harmony Biosciences